Home https://server7.kproxy.com/servlet/redirect.srv/sruj/smyrwpoii/p2/ Health https://server7.kproxy.com/servlet/redirect.srv/sruj/smyrwpoii/p2/ BNT162b2 induced neutralization of B.1.617 and other variants of SARS-CoV-2

BNT162b2 induced neutralization of B.1.617 and other variants of SARS-CoV-2



Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to develop worldwide, generating new variants that are of concern based on their potential for altered transmissibility, pathogenicity, and coverage by vaccines and therapeutics.1–5. Here we report that 20 human sera withdrawn 2 or 4 weeks after two doses of BNT162b2 neutralized the engineered SARS-CoV-2 of genetic origin USA-WA1 / 2020 (viral strain isolated in January 2020) and glycoproteins from new genera B.1.617.1, B.1.617.2, B.1.618 (all first identified in India) or B.1.525 (originally identified in Nigeria) Geometric mean plaque neutralization titers against variational viruses, in particular variant B .1.617.1 appear to be lower than the titer against virus USA-WA1 / 2020, but all sera tested neutralize variant viruses at titers of at least 40. The susceptibility of these emerging variants of vaccine-induced BNT1

62b2 supports mass immunization as a central strategy for ending the 2019 coronavirus disease pandemic (COVID-19) in different geographical areas.


Source link